Biogen Receives Favorable Decision from Court of Justice of the European Union Relating to TECFIDERA® (dimethyl fumarate) Regulatory Data and Marketing ProtectionGlobeNewsWire • 03/16/23
Caroline Dorsa to Succeed Stelios Papadopoulos as Chair of Biogen Board of DirectorsGlobeNewsWire • 03/08/23
Sage Therapeutics and Biogen Share Update on FDA Advisory Committee for ZuranoloneBusiness Wire • 03/08/23
Biogen Inc. (BIIB) 43rd Annual Cowen Healthcare Conference Conference (Transcript)Seeking Alpha • 03/06/23
FDA will review Eisai's and Biogen's Alzheimer's treatment Leqembi with decision on full approval expected in early JulyCNBC • 03/06/23
FDA Accepts Eisai's Filing of a Supplemental Biologics License Application and Grants Priority Review for Traditional Approval of LEQEMBI™ (lecanemab-irmb) for the Treatment of Alzheimer's DiseaseGlobeNewsWire • 03/05/23
Biologics License Application for Lecanemab Designated for Priority Review by China National Medical Products AdministrationGlobeNewsWire • 02/27/23
Biogen shares fall on 4Q results but Canaccord analysts remain optimistic about Alzheimer's drugProactive Investors • 02/15/23
Compared to Estimates, Biogen Inc. (BIIB) Q4 Earnings: A Look at Key MetricsZacks Investment Research • 02/15/23
Biogen Inches Higher On Quarterly Beat, Guides To 'Modest' Alzheimer's Drug SalesInvestors Business Daily • 02/15/23